Celltrion said on Jan. 7 that it will attend the JP Morgan Healthcare Conference in San Francisco. The world's largest event for the pharmaceutical and biotech industry will draw about 8,000 corporate executives and investors. Celltrion will present new drug development results and its contract manufacturing organization (CMO) business strategy.
Chief Executive Officer Seo Jin-seok of Celltrion will present on Jan. 13 (local time) at the event on new drug development results and the launch schedule for biosimilars (biosimilar). Executive Vice President Lee Hyeok-jae will outline strategies to expand product supply at the Branchburg, New Jersey, manufacturing site. The company recently completed the acquisition of the Branchburg manufacturing facility.
Celltrion is developing antibody-drug conjugates (ADCs) and multi-specific antibodies. ADCs are a technology that attaches a drug to an antibody to deliver it precisely to cancer cells, reducing side effects on normal cells while maximizing treatment efficacy. A Celltrion official said, "We will present a business direction that can grow in the global market."